Carcinoma in situ of endocervix
ICD-10 D06.0 is a billable code used to indicate a diagnosis of carcinoma in situ of endocervix.
Carcinoma in situ of the endocervix refers to a localized form of cervical cancer where abnormal cells are found in the lining of the endocervix but have not invaded deeper tissues or spread to other parts of the body. This condition is often detected through routine Pap smears or HPV testing, which can identify precancerous changes in cervical cells. The diagnosis of carcinoma in situ indicates that the cells are abnormal and have the potential to develop into invasive cancer if left untreated. Surveillance protocols typically involve regular follow-up examinations, including Pap tests and HPV testing, to monitor for any progression of the disease. Treatment options may include excisional procedures such as LEEP (Loop Electrosurgical Excision Procedure) or conization, which aim to remove the affected tissue. The risk of progression to invasive cervical cancer is significant, particularly if the carcinoma in situ is not managed appropriately, making early detection and intervention crucial.
Detailed pathology reports, treatment plans, and follow-up care notes.
Routine Pap smear results indicating abnormal cells, follow-up biopsies confirming carcinoma in situ.
Ensure accurate coding based on the specific location of the carcinoma and treatment interventions.
Comprehensive treatment history, including surgical interventions and ongoing surveillance.
Patients undergoing treatment for carcinoma in situ and those in surveillance post-treatment.
Documentation must reflect the patient's treatment response and any changes in diagnosis.
Used for treatment of diagnosed carcinoma in situ.
Pathology report confirming diagnosis and treatment plan.
Gynecologists must document the extent of excision and follow-up care.
Diagnosing carcinoma in situ is crucial as it indicates the presence of abnormal cells that have the potential to progress to invasive cancer if not treated. Early detection and management can significantly reduce the risk of progression.
